Join our daily newsletter At The Bell to receive exclusive market insights
- Genetic Technologies (GTG) will start selling its generation 3 breast cancer test next year
- The company has received full commissioning of its Australian Laboratory
- Genetype for breast cancer is the world first genomic test to accurately predict the risk of disease
- The company is currently looking to secure 12 clinics in Victoria and New South Wales
- Eligible Shareholders will be entitled to participate in a 2 for one offer of any of Genetic’s tests in any combination
- On market close, Genetic is up 25 per cent and is trading at 0.6¢ apiece
Genetic Technologies (GTG) will start selling its generation 3 breast cancer test next year.
The company has received full commissioning of its Australian Laboratory.
Breast cancer is one of the top cancers for women, with one in eight women diagnosed with the cancer. Genetic hopes to help women find the symptoms early to help get treated.
Genetype for breast cancer is the world first genomic test to accurately predict the risk of disease. It combines the information contained in DNA with family history and mammography data to create a powerful new tool in the battle with breast cancer.
Genetic says its test can accurately identify low-risk individuals (as low as 1/5 of average risk) as well as high-risk individuals (up to 5 times average risk).
Unlike the BRCA gene testing, which is used to detect 1 in 400 women who carry this cancer-associated genetic mutation, Genetpe is used for the better management of 95 per cent of all breast cancers which is referred to as sporadic (non-familial).
The tests are designed to complement current screening and not to replace them.
“By starting testing at the age of 35, Genetype is able to help identify some of the 20 per cent of breast cancers that occur before the age of 50, the age at which government-sponsored testing begins,” the company said.
Genetype’s platform technology is also able to help identify interval cancers by the targeted increased screening of high-risk individuals (interval cancers typically strike between the current 2 yearly screening cycles and may represent as many as 25 per cent of all new cancers).
The first phase of sales will allow early adopters to be offered the test in a medically supervised and integrated environment. Low to normal risk individuals will continue to be managed in a screening schedule e.g. 2 yearly mammograms from the age of 50.
High-risk individuals will be referred to screening centres where they will be offered a personalised service subject to their risk.
“High risk can be managed successfully by modifying lifestyle and increasing cancer screening,” the company said.
Genetic is currently looking to secure 6 clinics in Victoria and 6 in New South Wales, where its test kits can be purchased and the tests performed. The company will announce these clinics in the new year.
Genetype for breast cancer may reduce mortality today bu as much as 20 per cent with minimal costs, side effects and drug interactions of traditional anti-cancer therapy.
Eligible Shareholders will be entitled to participate in a 2 for one offer of any of Genetic’s tests in any combination, with full details of the offer to be provided shortly.
On market close, Genetic is up 25 per cent and is trading at 0.6¢ apiece.
